9 citations
,
August 2005 in “Experimental Dermatology” Modified pep7, named EPM peptide, effectively promotes hair growth at low concentrations and works well with minoxidil.
April 2016 in “British Journal of Dermatology” Eyelashes are important for looks and eye protection, and more people are treating sparse eyelashes; more research is needed to understand eyelash biology and improve treatments.
42 citations
,
March 2006 in “Drug Discovery Today: Therapeutic Strategies” The conclusion is that we need more effective hair loss treatments than the current ones, and these could include new drugs, gene and stem cell therapy, hormones, and scalp cooling, but they all need thorough safety testing.
20 citations
,
July 2011 in “PLoS ONE” HPV-150 and HPV-151 are rare skin viruses linked to warts and some skin cancers.
19 citations
,
August 2010 in “Journal der Deutschen Dermatologischen Gesellschaft” Certain plant extracts can effectively treat skin conditions like athlete's foot, chronic vein problems, sun damage, skin growths, vitiligo, and hair loss, and may also improve skin appearance.
1 citations
,
April 2016 in “British Journal of Dermatology” Buschke-Ollendorff syndrome is a rare genetic disorder causing skin and bone changes, with some cases also showing ADHD or developmental delays.
New peptides can delay aging and improve cell function.
June 2024 in “Research Square (Research Square)” Jagged-1 in skin Tregs is crucial for timely wound healing by recruiting specific immune cells.
February 2024 in “Frontiers in plant science” Peps help Arabidopsis plants grow more root hairs by affecting specific genes and calcium signaling.
May 2005 in “Molecular Carcinogenesis” mrp/plf-mRNA can indicate tumor-promoting effects in skin.
324 citations
,
May 2002 in “Oncogene” 4 citations
,
October 2024 in “Heliyon” CYP154C7 enzyme can effectively modify steroids and is promising for commercial use.
March 2026 in “Bioconjugate Chemistry” Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.
15 citations
,
November 2022 in “Cell Death and Disease” CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.
79 citations
,
October 2003 in “PubMed” Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.
March 2010 in “European Journal of Cancer Supplements” 
6 citations
,
February 2025 in “Scientific Reports” MEGA PROTAC improves prediction and ranking of protein complexes better than existing methods.
52 citations
,
May 2011 in “Journal of Neuroendocrinology” PEA boosts allopregnanolone production and reduces oxidative stress in brain cells.
87 citations
,
July 2018 in “Biochimica et Biophysica Acta (BBA) - Molecular Cell Research” Mice studies show that Protein Phosphatase 2A is crucial for cell growth, development, and disease prevention.
28 citations
,
December 2015 in “Journal of biological chemistry/The Journal of biological chemistry” Prostasin has two roles in skin: one for normal skin development without needing activation, and another for proper hair growth that requires activation.
14 citations
,
August 2014 in “The FASEB Journal” CAP1/Prss8 does not activate PAR2 or inhibit PN-1.
15 citations
,
March 2021 in “EMBO Reports” PRSS35 enzyme may help start skin tumors and could be a target for cancer treatment.
81 citations
,
February 2019 in “Experimental & Molecular Medicine” PAK4 is crucial in cancer progression, brain development, and could be a therapeutic target, especially through the PAK4-CREB axis.
54 citations
,
October 2023 in “Oncogene” p63 is essential for controlling epithelial stem cells and tissue health.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” The document discusses the submission of a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), a PROTAC protein degrader targeting the estrogen receptor, by Arvinas and Pfizer. This submission is based on positive results from the Phase 3 VERITAC-2 trial and marks a significant milestone as vepdegestrant is anticipated to be the first FDA-approved PROTAC degrader. PROTACs, a novel class of molecules, selectively degrade disease-causing proteins and offer advantages over traditional small molecule inhibitors, such as mitigating off-target effects and overcoming drug resistance. Despite concerns about their large molecular weight and drug-like properties, recent clinical results have been promising. The success of PROTACs has inspired the development of other chimeric molecules for therapeutic applications.
4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” Activated ras can protect kidney cells from a certain substance that causes cell death.
2 citations
,
January 2020 in “BioMed Research International” Phaeodactylum tricornutum extract helps hair follicle cells grow by activating the ERK1/2 pathway.
1 citations
,
March 2023 in “Science Translational Medicine” Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.
7 citations
,
April 2019 in “Animal biotechnology” The POMP gene is active in various goat tissues and affects hair growth, with certain treatments influencing its expression.
April 2018 in “Journal of Investigative Dermatology” CREB, a protein that can promote cancer traits, is controlled by β-catenin in skin cancer cells.